TNFRSF10A and renal cell carcinoma: Despite the presence of proapoptotic TRAIL-R1 and -R2 receptors in all cell lines, however, therapeutically relevant doses of IR combined with TRAIL treatment largely failed to increase the apoptotic response in most of our RCC cell lines.